ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2021
Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Astrocyte-driven vasoconstriction impairs glymphatic clearance in a human tauopathy-on-chip model.APL bioengineering · 2025Article
- Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- Investigating the Prognostic Role of Peripheral Inflammatory Markers in Mild Cognitive Impairment.Journal of clinical medicine · 2023Article
- Investigating the causal association between branched-chain amino acids and Alzheimer's disease: A bidirectional Mendelian randomized study.Frontiers in nutrition · 2023Article
- Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study.Journal of Alzheimer's disease : JAD · 2023Article
- Immune-mediated diseases are associated with a higher incidence of dementia: a prospective cohort study of 375,894 individuals.Alzheimer's research & therapy · 2022Article
- The health status: the ignored risk factor in dementia incidence. NEDICES cohort.Aging clinical and experimental research · 2022Article
- Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives.Neuroscience bulletin · 2022Review
- Peripheral immunity is associated with the risk of incident dementia.Molecular psychiatry · 2022Article
- Article
- Cross-Sectional Association Between Blood Cell Phenotypes, Cognitive Function, and Brain Imaging Measures in the Community-Based Framingham Heart Study.Journal of Alzheimer's disease : JAD · 2022Article
- Integrating peripheral blood and brain transcriptomics to identify immunological features associated with Alzheimer's disease in mild cognitive impairment patients.Frontiers in immunology · 2022Article
- Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- 12-year prediction of mild cognitive impairment aided by Alzheimer's brain signatures at mean age 56.Brain communications · 2021Article
- Peripheral immune markers in dementia: A systematic review and meta-analysis of risk, severity, and pathological correlates.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe investigated how components of immunity relate to biomarkers of Alzheimer's disease (AD) in plasma and explored the influence of AD genetic risk factors in the population-based Rotterdam Study.
methodsIn 7397 persons, we calculated the granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In 3615 of these persons, plasma amyloid-beta (Aβ)42 and Aβ40 were measured. Next, we constructed an overall genetic risk score (GRS) based on genome-wide significant variants, both including and excluding APOE ε4.
resultsAll innate immunity phenotypes were related to higher Aβ, most strongly with a doubling in GLR leading to a 1.9% higher Aβ42 (95% confidence interval [95% CI] 0.4 to 3.3%) and 3.2% higher Aβ40 (95% CI 2.0 to 4.3%). Higher AD GRS including APOE ε4 was associated with higher immunity markers. DISCUSSION: Higher levels of immunity markers were associated with higher Aβ in plasma. Participants with a higher genetic predisposition to AD had higher immunity markers, where these effects were mainly driven by APOE ε4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.